Mark R Albertini

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi request reprint In vivo mutant frequency of thioguanine-resistant T-cells in the peripheral blood and lymph nodes of melanoma patients
    M R Albertini
    Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    Mutat Res 476:83-97. 2001
  2. ncbi request reprint Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma
    Mark R Albertini
    University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA
    Cancer Chemother Biol Response Modif 22:789-97. 2005
  3. ncbi request reprint Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma
    Brian S Choi
    Department of Medicine, University of Wisconsin, Madison, 53792, USA
    Cancer Immunol Immunother 55:761-74. 2006
  4. pmc Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
    Mark R Albertini
    University of Wisconsin Carbone Cancer Center, Madison, WI, USA
    Cancer Immunol Immunother 61:2261-71. 2012
  5. pmc In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells
    Cindy L Zuleger
    University of Wisconsin, Carbone Cancer Center, WI, USA
    J Immunol Methods 365:76-86. 2011
  6. pmc Clonal expansions of 6-thioguanine resistant T lymphocytes in the blood and tumor of melanoma patients
    Mark R Albertini
    Medical Service, William S Middleton Memorial Veterans Hospital, Madison, Wisconsin 53705, USA
    Environ Mol Mutagen 49:676-87. 2008
  7. pmc Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients
    David M King
    University of Wisconsin, Madison, WI 53792, USA
    J Clin Oncol 22:4463-73. 2004
  8. pmc A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
    Kaci L Osenga
    The University of Wisconsin Madison, Madison, Wisconsin, USA
    Clin Cancer Res 12:1750-9. 2006
  9. pmc The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma
    Brett H Yamane
    The University of Wisconsin Madison, Departments of Surgery, WI 53792, USA
    Expert Opin Investig Drugs 18:991-1000. 2009
  10. ncbi request reprint Phase II trial of weekly paclitaxel in patients with advanced melanoma
    Leslie Walker
    Department of Medicine, University of Wisconsin, Madison, Wisconsin 53792, USA
    Melanoma Res 15:453-9. 2005

Collaborators

Detail Information

Publications18

  1. ncbi request reprint In vivo mutant frequency of thioguanine-resistant T-cells in the peripheral blood and lymph nodes of melanoma patients
    M R Albertini
    Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    Mutat Res 476:83-97. 2001
    ..Further studies will characterize the functional reactivity of hprt mutant isolates against melanoma-related antigens...
  2. ncbi request reprint Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma
    Mark R Albertini
    University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA
    Cancer Chemother Biol Response Modif 22:789-97. 2005
  3. ncbi request reprint Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma
    Brian S Choi
    Department of Medicine, University of Wisconsin, Madison, 53792, USA
    Cancer Immunol Immunother 55:761-74. 2006
    ..We conducted a phase I trial of interleukin 2 (IL-2) in combination with chimeric 14.18 (ch14.18) and murine R24 antibodies to determine the maximal tolerated dose (MTD), immunological effects, and toxicity of this treatment combination...
  4. pmc Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
    Mark R Albertini
    University of Wisconsin Carbone Cancer Center, Madison, WI, USA
    Cancer Immunol Immunother 61:2261-71. 2012
    ..We conclude that subsequent testing of hu14.18-IL2 should involve melanoma patients with minimal residual disease based on compelling preclinical data and the confirmed immune activation with some antitumor activity in this study...
  5. pmc In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells
    Cindy L Zuleger
    University of Wisconsin, Carbone Cancer Center, WI, USA
    J Immunol Methods 365:76-86. 2011
    ..We conclude that in vivo MT merit study as novel probes for uncharacterized immunogenic antigens in melanoma and other malignancies...
  6. pmc Clonal expansions of 6-thioguanine resistant T lymphocytes in the blood and tumor of melanoma patients
    Mark R Albertini
    Medical Service, William S Middleton Memorial Veterans Hospital, Madison, Wisconsin 53705, USA
    Environ Mol Mutagen 49:676-87. 2008
    ....
  7. pmc Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients
    David M King
    University of Wisconsin, Madison, WI 53792, USA
    J Clin Oncol 22:4463-73. 2004
    ..To evaluate the safety, toxicity, in vivo immunologic activation, and maximum-tolerated dose (MTD) of EMD 273063 (hu14.18-IL-2) in patients with metastatic melanoma...
  8. pmc A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
    Kaci L Osenga
    The University of Wisconsin Madison, Madison, Wisconsin, USA
    Clin Cancer Res 12:1750-9. 2006
    ..Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14.18-IL2 (EMD 273063) in pediatric patients with recurrent/refractory neuroblastoma and other GD2-positive solid tumors...
  9. pmc The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma
    Brett H Yamane
    The University of Wisconsin Madison, Departments of Surgery, WI 53792, USA
    Expert Opin Investig Drugs 18:991-1000. 2009
    ..Preclinical and initial clinical data suggest greater efficacy in the setting of minimal residual disease; therefore, future clinical testing is planned to test the benefit of EMD-273063 in this setting...
  10. ncbi request reprint Phase II trial of weekly paclitaxel in patients with advanced melanoma
    Leslie Walker
    Department of Medicine, University of Wisconsin, Madison, Wisconsin 53792, USA
    Melanoma Res 15:453-9. 2005
    ..Unfortunately, the anti-tumour activity of this single-agent therapy is low and additional treatment innovations are needed...
  11. pmc A conditional predictive p-value to compare a multinomial with an overdispersed multinomial in the analysis of T-cell populations
    Qinglin Pei
    Department of Statistics, University of Wisconsin, Madison, WI 53706, USA
    Biostatistics 15:129-39. 2014
    ..The procedure has a simple interpretation, requires fewer modeling assumptions than would be required of a fully Bayesian analysis, and has reasonable operating characteristics as evidenced empirically and by asymptotic analysis. ..
  12. ncbi request reprint A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients
    Ryan D Cassaday
    Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Clin Cancer Res 13:540-9. 2007
    ..The aims of this phase I study were to assess the safety and immunologic effects of PMED of these genes in melanoma patients...
  13. pmc MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair
    Neehar Bhatia
    Department of Medicine, University of Wisconsin, Carbone Cancer Center, Madison, Wisconsin 53705, USA
    J Invest Dermatol 133:759-67. 2013
    ....
  14. ncbi request reprint MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis
    Jason A Dubovsky
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI, USA
    J Immunother 30:675-83. 2007
    ..0001). These findings, along with the demonstration that MAD-CT-2 is expressed in melanoma cell lines, identified MAD-CT-2 as a novel melanoma CTA...
  15. pmc Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696
    John M Kirkwood
    Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 2584, USA
    Clin Cancer Res 15:1443-51. 2009
    ....
  16. ncbi request reprint Preclinical and clinical development of immunocytokines
    Paul M Sondel
    Department of Pediatrics, Human Oncology, Genetics and Medicine and the University of Wisconsin Comprehensive Cancer Center, The University of Wisconsin Madison, 600 Highland Avenue, Madison, WI 53792, USA
    Curr Opin Investig Drugs 4:696-700. 2003
    ..Clinical testing of ICs has recently begun using an anti-GD2 monoclonal antibody linked to interleukin-2 (IL-2) (hu14.18-IL-2), and using an antibody directed against the human epithelial cell adhesion molecule linked to IL-2 (KS-IL-2)...
  17. ncbi request reprint Dendritic cell-based immunotherapy for cancer and relevant challenges for transfusion medicine
    Ching Y Voss
    Department of Pathology and Laboratory Medicine, University of Wisconsin Madison, 53705, USA
    Transfus Med Rev 18:189-202. 2004
    ..The potential challenges for blood banking/transfusion medicine involving both technical and regulatory issues are discussed...
  18. ncbi request reprint Localization of transfected B7-1 (CD80) DNA in human melanoma cells after particle-mediated gene transfer
    Donna O McCarthy
    Comprehensive Cancer Center, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
    Cancer Genet Cytogenet 144:106-11. 2003
    ..These data suggest that B7-1 insertion may involve homologous recombination, but maintenance of integration and amplification required selection...